- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Shift to Value-Based Kidney Care Delivery in 2021
On this episode of Managed Care Cast, we speak with the new chief financial officer of Strive Health, a value-based kidney care company that works with payers and providers to create an integrated care delivery system for chronic kidney disease and end-stage renal disease (ESRD). We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to halt the slide to irreversible ESRD.
In 2021, CMS is launching new payment models to address the high cost of care for Medicare beneficiaries with kidney disease and to improve patient outcomes. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the most expensive conditions in Medicare; about 37 million Americans have CKD and 725,000 have ESRD. The situation is expected to get worse as the population ages, rates of diabetes and obesity soar, and demand for dialysis increases.
On this episode of Managed Care Cast, we speak with Brandi Riddle, who recently joined Strive Health as its chief financial officer. Strive Health is a value-based kidney care company that works with payers and providers to create an integrated care delivery system for CKD and ESRD. We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to try and halt the slide to irreversible ESRD.
Listen above or through one of these podcast services:
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
